Sanofi treatment of autoimmune hemolytic anemia granted orphan status
The FDA granted orphan designation to Sanofi US Services’ rilzabrutinib as a treatment of autoimmune hemolytic anemia, according to a post to the agency’s website. Discover th ...
The Financial Express6d
FDA gives nod to first rapid-acting insulin biosimilar for diabetes treatment
(Image Credits: Pixabay) The U.S. Food and Drug Administration (USFDA) on Friday approved Merilog as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and ...
Seeking Alpha4d
NVO Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...
Daily3d
Sanofi's Merilog Receives USFDA Approval as Biosimilar to Novolog for Diabetes Management
New Delhi: Sanofi has received U.S. Food and Drug Administration (FDA) approval for Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control in adults ...
BioSpace5d
Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market. Like its ...